NEW YORK (GenomeWeb) – Repositive and AstraZeneca this week named the inaugural members of the PDX Consortium, a group that was set up with the aim of developing a collaborative, pre-competitive resource of molecular data from patient-derived xenografts (PDXs) for use in oncology research. Inaugural members include AstraZeneca, Boehringer Ingelheim, Merck Group, Xentech, Xenopat, and Horizon Discovery.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.